Description; Application; ML-9 has been used in the inhibition of myosin light chain kinase (MLCK) and non-muscle myosin IIA (NMIIA) in human corneal epithelial cells and HeLa cells.; Packaging; 5 mg in glass bottle; Biochem/physiol Actions; ML-9 is myosin light chain kinase inhibitor. It inhibits insulin-induced translocation of glucose transporters GLUT4 and GLUT1 in a dose-dependent manner. ML-9 also inhibits agonist-induced Ca2+ entry into endothelial cells and catecholamine secretion in intact and permeabilized chromaffin cells. ML-9 promotes cell death in cancer cells by triggering accumulation of autophagic vacuoles. ML-9 impacts phosphorylation of myosin light chain kinase and alters trabecular meshwork shape and decreases intraocular pressure in rabbit eyes.; Features and Benefits; This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.; This compound is featured on the Ca/CaMKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.; Legal Information; LOPAC is a registered trademark of Sigma-Aldrich Co. LLC